Prevalence and Correlates of Symptoms of Cannabinoid Hyperemesis Syndrome in the United States, 2025.

Objectives. To characterize the potential prevalence of cannabinoid hyperemesis syndrome (CHS) symptoms and associated characteristics. Methods. Using data from a nationally representative survey of 7034 US adults (conducted May‒September 2025), we fit separate survey-weighted multinomial logistic regression models with a 4-category CHS-symptom and cannabis-use group variable as the outcome and demographic characteristics, cannabis-use behaviors, and cannabis use‒related problems as predictors. Results. Overall, 2.7% of all respondents and 17.8% of respondents who used cannabis daily reported CHS-like symptoms. Respondents who were younger, female, identified as non-White, had lower income, had lower educational attainment, and endorsed cannabis use‒related problems were more likely to be in the CHS-symptom group than in the daily-cannabis-use group. Conclusions. CHS symptoms are not uncommon in the United States, and those with fewer economic resources and more cannabis use‒related problems were more likely to report these symptoms, even compared with others with daily cannabis use. Public Health Implications. As cannabis use increases, CHS is also likely to become more common, underscoring the importance of expanded education about the identification and treatment of CHS. (Am J Public Health. Published online ahead of print October 1, 2026:e1-e10. https://doi.org/10.2105/AJPH.2026.308753).